Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Generics File Fewer Patent Challenges In New Era

This article was originally published in PharmAsia News

Executive Summary

Indian drug makers are backing away from their tendency to challenge the patents of branded drugs in favor of taking a more cautious approach. As a result, the number of patent challenges filed in the United States by Indian pharmas in the past few years has declined by nearly half. The trend has been slowed in part because the owners of those patents have been taking steps to compete with the generics makers for specific drugs. As a result, Dr. Reddy's, Glenmark, Ranbaxy, Sun Pharma and Wockhardt are becoming more selective in their challenges. (Click here for more
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069430

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel